ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2025
Autophagy-Targeting Fe-Cu Nanozyme for Tumor Immune Microenvironment Remodeling and Image-Guided Cancer Immunotherapy.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Nanomaterial-driven spatiotemporal autophagy modulation: The dual-edged sword in precision cancer therapy.Acta pharmaceutica Sinica. B · 2026Review
- Autophagy-Targeting Fe-Cu Nanozyme for Tumor Immune Microenvironment Remodeling and Image-Guided Cancer Immunotherapy.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
Abstract
The suppressive tumor immune microenvironment (TIME) is a critical driver of tumor progression, immune evasion, and therapy resistance. Despite the transformative potential of immunotherapy, autophagy within the TIME weakens immune surveillance by downregulating tumor cell surface major histocompatibility complex class I (MHC-I) expression, thereby facilitating immune escape. Here, a novel nanozyme-based strategy is reported to modulate autophagy and restore anti-tumor immunity. Iron-copper metal-organic frameworks (Fe-Cu MOFs) are engineered with tunable peroxidase, glutathione peroxidase, and oxidase-like activities, and an optimal Fe:Cu ratio that confers potent redox activity alongside robust inhibition of autophagic flux is identified. These MOF nanozymes selectively impair autophagy and restore MHC-I expression in tumor cells, enhancing immune recognition. To further potentiate autophagic blockade, a multifunctional nanoplatform (FCMP@CQ/PFH) is developed by co-loading low-dose chloroquine (CQ) and encapsulating perfluorohexane (PFH) into the Fe-Cu MOFs. This combinatorial system couples nanozyme-driven redox stress with lysosomal inhibition to synergistically suppress autophagy and reinvigorate anti-tumor immune responses. Moreover, PFH facilitates ultrasound-based real-time visualization of therapeutic efficacy. Both in vitro and in vivo studies show that FCMP@CQ/PFH enhances cancer immunotherapy and suppresses metastasis. This study establishes a dual-functional approach that combines autophagy inhibition with immune microenvironment reprogramming to circumvent immune resistance and advance precision cancer immunotherapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.